ArticleLung cancer management2026
CyberKnife radical cure for early lung adenocarcinoma: a case was confirmed by postoperative pathology.
Article in Lung cancer management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The utilization of pathological assessment to evaluate tumor response in patients with early-stage non-small cell lung cancer (NSCLC) has not been documented in the extant literature. A 64-year-old male patient with lung adenocarcinoma was treated with CyberKnife. A subsequent review of the images suggested that the mass in the area of radiotherapy had increased in size compared to the previous one, suggesting tumor recurrence. Consequently, surgery was performed to remove the enlarged mass. Postoperative histopathology showed no tumor tissue. This case underscores the potential efficacy of CyberKnife in the treatment of early-stage non-small cell lung cancer (NSCLC) tumors and confirms its effectiveness as a radical treatment modality, as validated by the gold standard of postoperative pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.